Liposomal Bupivacaine in Total Knee Arthroplasty | NCT02426164 | Trialant

Liposomal Bupivacaine in Total Knee Arthroplasty | NCT02426164 | Trialant

Sponsor/Collaborators Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Liposomal bupivacaine	Active Comparator	Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants	Drug: Liposomal bupivacaine
bupivacaine HCl, morphine, epinephrine, methylprednisolone	Active Comparator	Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants	Drug: bupivacaine HCl, morphine, epinephrine, methylprednisolone

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Mean visual analog scale (VAS) pain scores	Self-reported pain scores from 0=no pain to 10=severe pain	Night of surgery
Mean visual analog scale (VAS) pain scores	Self-reported pain scores from 0=no pain to 10=severe pain	Post-operative day 1
Mean visual analog scale (VAS) pain scores	Self-reported pain scores from 0=no pain to 10=severe pain	Post-operative day 2
Pain assessment phone call	Subjects will be called on post-operative day three by one of the investigators of the study. Subjects will be asked to rate their current pain level from 1 to 10 and to rate their worst pain level from 1 to 10 that day.	Post-operative day 3

Secondary Outcomes

Measure	Description	Time Frame
Complications	Number of patients with complications	Complications will be followed for the duration of patients' hospital stay, an expected average of 2-3 days.

Contacts/Locations Module

Condition Browse Module

Intervention Browse Module